Inappropriately elevated endothelin-1 plays a role in the pathogenesis of intradialytic hypertension

Jie Teng1, Jie Tian, Wen-Lv Lv

  • 1Department of Nephrology, Zhongshan Hospital, Shanghai Medical College, Fudan University, No 180 Fenglin Road, Shanghai, 200032, China; Kidney and Dialysis Institute of Shanghai, No 180 Fenglin Road, Shanghai, 200032, China; Kidney and Blood Purification Laboratory of Shanghai, No 180 Fenglin Road, Shanghai, 200032, China.

Hemodialysis International. International Symposium on Home Hemodialysis
|October 28, 2014
PubMed

Insights

Elevated endothelin-1 (ET-1) plasma levels are linked to intradialytic hypertension (IDH) in hemodialysis patients. This finding suggests ET-1 plays a key role in the development of IDH during dialysis.

Area of Science:

  • Nephrology
  • Cardiovascular Physiology
  • Biochemistry

Background:

  • Intradialytic hypertension (IDH) is a complication during maintenance hemodialysis.
  • The role of endogenous vasoactive substances in IDH pathogenesis requires further investigation.

Purpose of the Study:

  • To investigate the effects of endogenous vasoactive substances on the occurrence of intradialytic hypertension (IDH) in patients undergoing maintenance hemodialysis.

Main Methods:

  • Retrospective comparison of 34 maintenance hemodialysis patients (17 with IDH, 17 controls).
  • Measurement of plasma levels of vasoactive substances (e.g., endothelin-1, nitric oxide, aldosterone) pre- and post-dialysis.
  • Analysis of blood pressure changes during hemodialysis sessions.

Main Results:

  • Post-dialysis endothelin-1 (ET-1) concentrations were significantly higher in IDH patients compared to controls.
  • The ratio of nitric oxide (NO) to ET-1 was significantly lower in IDH patients post-dialysis.
  • Aldosterone and norepinephrine levels showed different pre- to post-dialysis changes in controls versus IDH patients.

Conclusions:

  • Inappropriately elevated ET-1 plasma concentrations appear to play a predominant role in the pathogenesis of IDH.
  • The balance between vasoconstrictors like ET-1 and vasodilators like NO is crucial in IDH development.
  • Further research into ET-1 modulation could offer therapeutic strategies for IDH.

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.6K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
7.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
600
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K